Related Experiment Videos

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas

J H Edmonson, H J Long, R L Richardson

Cancer Chemotherapy and Pharmacology

|January 1, 1985

Abstract:

In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

Bone marrow transplantation·2009

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

Sarcoma·2008

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.

Gene therapy·2005

Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer.

American journal of clinical oncology·2002

Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.

Cancer investigation·2001

See all related articles